Cargando…

Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis

OBJECTIVES: To examine which composite measures are most sensitive to change when measuring psoriatic arthritis (PsA) disease activity, analyses compared the responsiveness of composite measures used in a 48-week randomized, controlled trial of MTX and etanercept in patients with PsA. METHODS: The t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Coates, Laura C, Merola, Joseph F, Mease, Philip J, Ogdie, Alexis, Gladman, Dafna D, Strand, Vibeke, van Mens, Leonieke J J, Liu, Lyrica, Yen, Priscilla K, Collier, David H, Kricorian, Gregory, Chung, James B, Helliwell, Philip S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7937022/ https://www.ncbi.nlm.nih.gov/pubmed/32864685 http://dx.doi.org/10.1093/rheumatology/keaa271

Ejemplares similares

Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial
por: Mease, Philip J., et al.
Publicado: (2019)

Patient-reported outcomes data in patients with psoriatic arthritis from a randomised trial of etanercept and methotrexate as monotherapy or in combination
por: Strand, Vibeke, et al.
Publicado: (2021)

Design and rationale of the Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects with Psoriatic Arthritis (SEAM-PsA)
por: Mease, Philip J, et al.
Publicado: (2018)

Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial
por: Helliwell, Philip S, et al.
Publicado: (2022)

Classification and Outcome Measures for Psoriatic Arthritis
por: Leung, Ying Ying, et al.
Publicado: (2018)

Inhibition of Interleukin-17 in Patients with Oligoarticular Psoriatic Arthritis
por: Ogdie, Alexis, et al.
Publicado: (2023)

Real‐World Evidence Assessing Psoriatic Arthritis by Disease Domain: An Evaluation of the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
por: Mease, Philip J., et al.
Publicado: (2023)

Measurement properties of the minimal disease activity criteria for psoriatic arthritis
por: Coates, Laura C, et al.
Publicado: (2019)

Treatment guidelines in psoriatic arthritis
por: Ogdie, Alexis, et al.
Publicado: (2020)

Systematic literature review of domains assessed in psoriatic arthritis to inform the update of the psoriatic arthritis core domain set
por: Kalyoncu, Umut, et al.
Publicado: (2016)

Qualifying Unmet Needs and Improving Standards of Care in Psoriatic Arthritis
por: Helliwell, Philip, et al.
Publicado: (2014)

Sex differences in the efficacy, safety and persistence of patients with psoriatic arthritis treated with tofacitinib: a post-hoc analysis of phase 3 trials and long-term extension
por: Eder, Lihi, et al.
Publicado: (2023)

Treatment‐to‐Target With Apremilast in Psoriatic Arthritis: The Probability of Achieving Targets and Comprehensive Control of Disease Manifestations
por: Mease, Philip J., et al.
Publicado: (2020)

Etanercept or Methotrexate Withdrawal in Rheumatoid Arthritis Patients in Sustained Remission
por: Curtis, Jeffrey R., et al.
Publicado: (2021)

Assessing structural damage progression in psoriatic arthritis and its role as an outcome in research
por: van der Heijde, Désirée, et al.
Publicado: (2020)

Sustained remission with methotrexate monotherapy after 22-week induction treatment with TNF-alpha inhibitor and methotrexate in early psoriatic arthritis: an open-label extension of a randomized placebo-controlled trial
por: de Jong, Henriëtte M. Y., et al.
Publicado: (2019)

Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placebo‐Controlled Study
por: Kavanaugh, Arthur, et al.
Publicado: (2016)

Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1
por: Strand, Vibeke, et al.
Publicado: (2021)

Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1)
por: Gottlieb, Alice B, et al.
Publicado: (2018)

Effects of Disease-Worsening Following Withdrawal of Etanercept or Methotrexate on Patient-Reported Outcomes in Patients With Rheumatoid Arthritis: Results From the SEAM-RA Trial
por: Curtis, Jeffrey R., et al.
Publicado: (2023)

Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT
por: Gladman, Dafna D, et al.
Publicado: (2010)

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
por: Gladman, Dafna D., et al.
Publicado: (2022)

Comparative effectiveness of biologic monotherapy versus combination therapy for patients with psoriatic arthritis: results from the Corrona registry
por: Mease, Philip J, et al.
Publicado: (2015)

Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden—a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs
por: Strand, Vibeke, et al.
Publicado: (2019)

Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial
por: Mease, Philip J, et al.
Publicado: (2017)

Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond
por: Strand, Vibeke, et al.
Publicado: (2019)

Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis: protocol of a randomized, placebo-controlled, double-blind clinical trial (COMPLETE-PsA)
por: Mulder, Michelle L. M., et al.
Publicado: (2020)

Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib
por: Coates, Laura C., et al.
Publicado: (2021)

Systematic literature review of non-topical treatments for early, untreated (systemic therapy naïve) psoriatic disease: a GRAPPA initiative
por: De Marco, Gabriele, et al.
Publicado: (2020)

Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis
por: Coates, Laura C, et al.
Publicado: (2022)

Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment
por: Strand, Vibeke, et al.
Publicado: (2012)

International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials
por: Orbai, Ana-Maria, et al.
Publicado: (2017)

Clinical Characteristics of Registry Participants with Psoriatic Arthritis Initiating Guselkumab: An Analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
por: Mease, Philip J., et al.
Publicado: (2022)

Psoriatic arthritis
por: Ocampo D, Vanessa, et al.
Publicado: (2019)

Assessing Disease Activity in Psoriatic Arthritis: A Literature Review
por: Tucker, Laura J., et al.
Publicado: (2018)

Predicting adherence to therapy in rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis: a large cross-sectional study
por: Smolen, Josef S, et al.
Publicado: (2019)

Patient’s experience of psoriatic arthritis: a conceptual model based on qualitative interviews
por: Ogdie, Alexis, et al.
Publicado: (2020)

Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study
por: Mease, Philip J, et al.
Publicado: (2020)

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021
por: Coates, Laura C., et al.
Publicado: (2022)

Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials
por: Mease, Philip J, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_apkvluparvm5kpk5hkvsvf40v9